US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
pharma · Acute Myeloid Leukemia · Acute Leukemia · ATNM
Actinium Pharmaceuticals
Actinium Pharmaceuticals drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
New York, USA HQ
2000 Founded
58 Employees
Public company Type
ATNM · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2000
- Employees
- 58
- Programs
- 8
- Drugs
- 4
- Patents
- 20
Actinium Pharmaceuticals pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Actinium Pharmaceuticals drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Actinium Pharmaceuticals in public FDA and regional records.
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Actinium Pharmaceuticals in public FDA and regional records.